Jun. 26 at 7:43 PM
$BCTX More isn't better, but multiple shots on goal IS better.
If a patient is HR+, you can't just pile-on with every hormone therapy at once, you have to be selective. Similarly, if the patient is HER2+, you can't use multiple HER2-targeted therapies, because they'd compete with each other to engage these expressions on the cancer cells. Again, you have to choose. The same is true for various kinase inhibitors, selective estrogen receptor modulators, ADCs, etc.
Chemo and CPIs are often used in combination with these other therapies, simply because they work differently. They don't target the same expressions, so they work as a complement. In some cases, they work synergistically.
While BriaCell has tested their cell line as monotherapy and with CPI, there is a huge, additional opportunity to work in conjunction with other, approved therapies. It doesn't target the cancer directly, at all. Thus, it can't interfere with the MOA of other approaches.
Perfect harmony in earlier lines...
